Anti-inflammatory compounds that target chronic inflammation pathways and support whole-body recovery.
31 itemsHow hot water vs dual extraction changes the immune-active compounds in mushrooms like reishi and turkey tail (PSK/PSP)—and what research suggests for immune support.
A focused, evidence-based review of how zinc supports immunity and what randomized trials say about using zinc lozenges to shorten the common cold, with practical caveats and traditional food insights.
A focused, evidence-based look at how chronic stress relates to telomere length, what interventions may help, and why the effects are modest and nuanced.
Does resveratrol truly activate sirtuins in humans? A concise, evidence-based look at the science, controversies, bioavailability, and how it compares with other polyphenols.
Research-backed look at whether post-workout cold exposure blunts muscle growth, how it compares with contrast therapy, and when it may still help recovery.
Animal studies suggest BPC-157 may support tendon, ligament, and muscle repair via angiogenesis and anti-inflammatory pathways, but human trials are lacking and it’s prohibited in sport.
A focused look at how mushroom beta‑glucans interact with the immune system and why hot‑water vs dual extraction changes their effects, with evidence from mechanistic studies and human trials.
Does post-workout cold exposure reduce muscle growth? This focused review summarizes RCTs and meta-analyses on cold water immersion after lifting and its impact on hypertrophy and strength.
Research-backed look at how gut microbiome diversity relates to autoimmune risk, mechanisms, early-life factors, diet patterns, and traditional perspectives.
Confused about zonulin tests for leaky gut? Learn what zonulin is, why commercial tests are debated, and how results relate to true intestinal permeability.
Zonulin biology is real, but commercial zonulin tests for “leaky gut” are inconsistent. Here’s what research says about tight junctions, test validity, clinical relevance, and evidence-based ways to support the gut barrier.
Research suggests zinc, especially as well-formulated lozenges taken early, may shorten the common cold. Learn how zinc supports immunity, which formulations matter, safety notes, and traditional zinc-rich foods.
Do zinc lozenges really shorten colds? An evidence-based look at timing, formulation, benefits, and safety—without dosing advice.
A focused look at the NIA Interventions Testing Program’s findings on rapamycin, how it intersects with caloric restriction and mTOR, current human and dog trials, risks, and why researchers remain cautiously optimistic.
Does a cold plunge after lifting blunt muscle growth? A focused, evidence-based look at timing, recovery trade-offs, and how ice baths compare with contrast therapy.
A focused look at L‑glutamine’s role in athlete immune health, why gut barrier support may matter more than colds prevention, and how traditional broth wisdom aligns with modern research.
Animal research suggests BPC-157 may support tendon and ligament repair via angiogenesis and anti-inflammatory pathways, but human RCTs are lacking and the peptide is not approved for medical use.
Zonulin tests are widely marketed for “leaky gut,” but research shows analytical limitations and unclear clinical value. Learn what serum and stool zonulin really measure, how they compare with lactulose–mannitol testing, and what conventional medicine accepts versus what remains debated.
Do zinc lozenges shorten a cold? Research suggests properly formulated zinc lozenges may reduce duration if started early. Learn mechanisms, evidence, and cautions.
A focused look at rapamycin and the mTOR pathway in longevity: ITP mouse findings, how caloric restriction converges on mTOR, the status of human and dog trials, potential risks, and natural mTOR modulators—why the field is hopeful yet cautious.
Does post-exercise cold water immersion blunt hypertrophy? A focused review of RCTs and meta-analyses on muscle growth, strength, and recovery trade-offs.
A focused review on L‑glutamine and exercise‑induced gut permeability in athletes—mechanisms, small RCTs, immune links, and traditional bone broth context.
Animal studies suggest BPC‑157 may influence tendon and ligament healing via angiogenesis and fibroblast pathways, but no human trials confirm benefit. Not approved for medical use and prohibited by WADA.
Learn how hot water and dual extracts of medicinal mushrooms shape beta-glucans, triterpenes, and immune modulation—plus evidence on turkey tail PSK/PSP and reishi.
A rich source of EPA and DHA omega-3 fatty acids, commonly used to support cardiovascular health and reduce inflammation.
Omega-3 fatty acids — specifically EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — are polyunsaturated fats that the human body cannot synthesize de novo. They must be obtained from dietary sources, primarily fatty fish (salmon, mackerel, sardines, anchovies), shellfish, and marine algae. EPA and DHA serve as structural components of cell membranes throughout the body, with particularly high concentrations in the brain (DHA comprises roughly 40% of polyunsaturated fatty acids in the brain) and retina. Beyond structural roles, they are precursors to specialized pro-resolving mediators (SPMs) — resolvins, protectins, and maresins — that actively resolve inflammation rather than simply suppressing it. The evidence base for omega-3 supplementation is extensive. Large-scale trials and meta-analyses support benefits for cardiovascular health (triglyceride reduction, modest blood pressure lowering), inflammatory conditions, mood disorders, and cognitive maintenance. The American Heart Association recommends at least two servings of fatty fish per week, and higher-dose EPA supplementation has been shown to reduce cardiovascular events in the REDUCE-IT trial.
A bright yellow spice derived from the Curcuma longa plant, widely used in Ayurvedic and traditional medicine for its anti-inflammatory properties.
Osteoarthritis (OA) is the most common arthritis, driven by age, mechanical loading, prior injury, obesity, and genetics. It features progressive cartilage loss, subchondral bone changes, synovial activation, and periarticular muscle weakness. Patients typically report activity-related joint pain, stiffness (often <30 minutes in the morning), reduced function, and sometimes swelling or crepitus. Knees, hips, hands, and spine are most affected. Diagnosis is clinical, supported by radiographs showing joint-space narrowing, osteophytes, and sclerosis; MRI is rarely required for routine care. Western management prioritizes nonpharmacologic strategies with the strongest, most consistent benefits across guidelines: education, exercise therapy (aerobic, strengthening, neuromuscular/balance), and weight reduction for those with overweight/obesity. Topical NSAIDs are recommended as first-line pharmacologic therapy for knee and hand OA, with oral NSAIDs used when needed and appropriate. Acetaminophen has diminishing evidence of benefit. Duloxetine can help chronic OA pain, particularly knee OA. Intra-articular corticosteroid injections offer short-term relief; hyaluronic acid remains controversial with mixed evidence. Platelet-rich plasma (PRP) injections are emerging but heterogeneous and not yet guideline-endorsed broadly. Joint replacement is highly effective for end-stage disease. Eastern and traditional approaches conceptualize OA differently but often converge on movement-based and symptom-relieving therapies. In Traditional Chinese Medicine (TCM), OA commonly maps to Bi syndrome (painful obstruction) with patterns such as wind-cold-damp Bi, blood stasis, and kidney (shen) deficiency. Treatment may include acupuncture (including electroacupuncture and warm-needle techniques), moxibustion, topical herbal liniments (e.g., capsicum), tuina/manual therapy, and herbal formulas (e.g., Du Huo Ji Sheng Tang). Acupuncture for knee OA is among the best-studied TCM applications,
Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune synovitis that, without timely control, leads to pain, progressive joint damage, disability, and increased cardiovascular risk. Western medicine defines RA by characteristic clinical patterns, serologic autoantibodies, and inflammatory markers, and prioritizes early, aggressive disease modification using a treat‑to‑target strategy. This approach, guided by rigorous randomized trials and international guidelines, has transformed outcomes—many patients can now achieve low disease activity or remission and preserve function. Diagnosis in Western practice uses ACR/EULAR classification criteria that integrate joint involvement, rheumatoid factor (RF) and anti‑cyclic citrullinated peptide (anti‑CCP) antibodies, acute‑phase reactants (ESR/CRP), and symptom duration. Imaging (ultrasound/MRI) can detect subclinical synovitis and erosions early. Management begins promptly—ideally within weeks of symptom onset—because early window therapy improves long‑term trajectories. First‑line conventional synthetic disease‑modifying antirheumatic drugs (csDMARDs) include methotrexate (anchor), sulfasalazine, hydroxychloroquine, and leflunomide. If targets (remission/low disease activity) are not met, biologic DMARDs (e.g., TNF, IL‑6, T‑cell costimulation, anti‑CD20) or targeted synthetic JAK inhibitors are added or substituted, with iterative monitoring every 1–3 months and shared decision‑making. Short glucocorticoid courses are sometimes used as a bridge, while NSAIDs treat pain but do not alter disease course. Safety monitoring, vaccination, infection screening, and comorbidity risk reduction (e.g., cardiovascular prevention, bone health, smoking cessation, exercise, rehabilitation) are integral. Eastern and traditional systems conceptualize RA differently but share aims of reducing pain, swelling, and functional limitations while preventing chronic deterioration. Traditional Chinese Medicine (TCM) frames RA within “Bi” (B
Arthritis (an umbrella term that includes inflammatory types such as rheumatoid arthritis and non‑inflammatory types such as osteoarthritis) and osteoporosis frequently intersect in mid‑ to late‑li...
Psoriasis is a chronic, immune-mediated skin disease affecting roughly 2–3% of the population. Psoriatic arthritis (PsA) is an inflammatory arthropathy that occurs in a substantial subset of people...
